Incorporation of rituximab and liposomal doxorubicin into CODOX-m/IVAC for HIV-negative and HIV-positive adult patients (pts) with untreated Burkitt's lymphoma (BL): Preliminary results of a multicenter phase II study.

8033 Background: The survival of adult BL has improved with intensification of multiagent chemotherapy, although 2-year survival rates remain 10 cm. All other pts were high risk (HR). LR pts received 3 CODOX-M cycles, while HR pts received 4 alternating cycles of CODOX-M and IVAC. Liposomal doxorubicin (40 mg/m2) was used in lieu of doxorubicin (day 1 CODOX-M) and rituximab (500 mg/m2) was added days 0 + 8 of CODOX-M and days 0 + 6 of IVAC. Methotrexate dose was 3,000 mg/m2 iv. Results: 18 pts have enrolled, of whom 12 were in the first stage. The median age was 43 years (23-70), 3/12 pts had HIV+ disease, and 9/12 had HR disease. Similar to previous CODOX-M/IVAC data, myelosuppression was common (83% grade 4 neutropenia and t...